Eledon Pharmaceuticals, Inc.
$4.14
▲
2.33%
2026-04-21 06:36:01
eledon.com
NCM: ELDN
Explore Eledon Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$314.03 M
Current Price
$4.14
52W High / Low
$4.6 / $1.35
Stock P/E
—
Book Value
$1.81
Dividend Yield
—
ROCE
-55.26%
ROE
-35.79%
Face Value
—
EPS
$-0.52
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
33
Beta
0.84
Debt / Equity
0.47
Current Ratio
7.4
Quick Ratio
7.4
Forward P/E
-3.86
Price / Sales
—
Enterprise Value
$102.45 M
EV / EBITDA
—
EV / Revenue
—
Rating
Strong Buy
Target Price
$8
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Creative Medical Technology Holdings, Inc. | $2.26 | — | $9.13 M | — | -81.64% | -86.47% | $6.25 / $1.5 | $2.03 |
| 2. | Celldex Therapeutics, Inc. | $34.38 | — | $2.7 B | — | -54.02% | -40.62% | $35.29 / $17.45 | $7.92 |
| 3. | Kyntra Bio, Inc. | $7.34 | 0.16 | $29.62 M | — | -50.18% | -143.52% | $12.6 / $4.85 | $-7.42 |
| 4. | Dermata Therapeutics, Inc. | $1.34 | — | $5.47 M | — | -124.91% | -1.94% | $9.9 / $1.1 | $2.34 |
| 5. | TG Therapeutics, Inc. | $36.96 | 12.6 | $5.64 B | — | 13.56% | 1.03% | $46.48 / $25.28 | $4.52 |
| 6. | Monte Rosa Therapeutics, Inc. | $19.81 | — | $1.58 B | — | -14.1% | -16.94% | $25.77 / $3.51 | $3.56 |
| 7. | Aura Biosciences, Inc. | $7.05 | — | $467.66 M | — | -74.67% | -73.52% | $7.48 / $4.34 | $2.15 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -21.48 M | -19.07 M | -24.73 M | -17.96 M | -24.7 M | — |
| Net Profit | -10.45 M | -17.46 M | -11.22 M | -6.5 M | -44.62 M | — |
| EPS in Rs | -0.14 | -0.23 | -0.15 | -0.09 | -0.59 | -0.32 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -83.25 M | -70.58 M | -43 M | -39.78 M |
| Net Profit | -45.62 M | -36.18 M | -116.54 M | -87.97 M |
| EPS in Rs | -0.6 | -0.48 | -1.54 | -1.16 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 169.01 M | 177.41 M | 89.07 M | 92.79 M |
| Total Liabilities | 87.92 M | 114.96 M | 81.86 M | 8.61 M |
| Equity | 81.08 M | 62.45 M | 7.21 M | 84.18 M |
| Current Assets | 135.69 M | 143.73 M | 56.13 M | 59.52 M |
| Current Liabilities | 18.34 M | 11.58 M | 3.9 M | 6.47 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -62.34 M | -47.27 M | -39.53 M | -28.42 M |
| Investing CF | 10.79 M | -70.31 M | -45.29 M | 0 M |
| Financing CF | 53.81 M | 133.52 M | 33.02 M | 0 M |
| Free CF | -62.34 M | -47.27 M | -39.53 M | -28.42 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 68.95% | -32.48% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.